Amphastar Pharmaceuticals (AMPH) Change in Receivables (2013 - 2026)

Amphastar Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 43.69% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 56.62% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, down 70.62% from the prior year.
• Change in Receivables rose to $4.5 million in Q1 2026 per AMPH's latest filing, from -$3.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $23.2 million in Q1 2024 and bottomed at -$12.3 million in Q2 2025.
• The 5-year median for Change in Receivables is $4.5 million (2026), against an average of $4.0 million.
• Across the five-year window, Change in Receivables surged 1430.46% in 2022 and tumbled 428.82% in 2024, its largest moves.
• Year by year, Change in Receivables stood at $11.6 million in 2022, then plunged by 135.39% to -$4.1 million in 2023, then gained by 28.93% to -$2.9 million in 2024, then fell by 11.22% to -$3.2 million in 2025, then jumped by 240.69% to $4.5 million in 2026.
• Per Business Quant, the three latest AMPH Change in Receivables figures stand at $4.5 million (Q1 2026), -$3.2 million (Q4 2025), and $13.8 million (Q3 2025).